Artivion, Inc. (NYSE:AORT) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Consensus "Moderate Buy" — Eight analysts cover Artivion (NYSE:AORT): six have a buy rating and two a hold, with an average 12‑month target price of $50.47.
• Recent quarter beat expectations — Artivion reported $0.17 EPS vs. $0.14 expected and revenue of $118.3M (up 19.2% year‑over‑year); analysts expect about $0.37 EPS for the fiscal year.
• Notable insider selling — Insiders sold 133,043 shares (~$4.98M) over the last 90 days, though they still own 7.60% of the company's stock.

Shares of Artivion, Inc. (NYSE:AORT - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $50.4667.

A number of equities research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Artivion from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Canaccord Genuity Group cut their price objective on shares of Artivion from $51.00 to $48.00 and set a "buy" rating on the stock in a report on Friday, February 13th. Weiss Ratings raised shares of Artivion from a "sell (d)" rating to a "hold (c-)" rating in a research report on Friday, February 20th. Stifel Nicolaus set a $55.00 target price on Artivion in a research report on Thursday, March 5th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $58.00 target price on shares of Artivion in a research report on Monday, February 2nd.

Artivion Stock Performance

Artivion stock opened at $35.18 on Friday. The firm has a market capitalization of $1.68 billion, a PE ratio of 175.93 and a beta of 1.60. Artivion has a one year low of $21.97 and a one year high of $48.25. The stock's 50 day moving average price is $38.58 and its 200 day moving average price is $42.08. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The business's revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, sell-side analysts expect that Artivion will post 0.37 EPS for the current fiscal year.

Insider Activity at Artivion

In other Artivion news, CAO Amy Horton sold 901 shares of Artivion stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $34,039.78. Following the sale, the chief accounting officer directly owned 139,088 shares in the company, valued at $5,254,744.64. The trade was a 0.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Lance A. Berry sold 6,316 shares of the company's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $238,618.48. Following the completion of the transaction, the executive vice president directly owned 210,827 shares in the company, valued at approximately $7,965,044.06. The trade was a 2.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 133,043 shares of company stock worth $4,977,158 over the last ninety days. Company insiders own 7.60% of the company's stock.

Institutional Trading of Artivion

Several institutional investors have recently added to or reduced their stakes in AORT. Aster Capital Management DIFC Ltd grew its holdings in Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company's stock worth $27,000 after acquiring an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion in the 3rd quarter worth about $27,000. Rockefeller Capital Management L.P. raised its stake in shares of Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock valued at $30,000 after purchasing an additional 399 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company's stock valued at $43,000 after purchasing an additional 563 shares in the last quarter. Finally, USA Financial Formulas lifted its position in shares of Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company's stock worth $52,000 after purchasing an additional 703 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.